Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Prothena Corp. plc
Industry Sector: HealthTechnology
CEO: Gene G. Kinney, PhD
Number Of Employees: 163
Enterprise Value: $284,197,196
PE Ratio: -4.91
Exchange/Ticker 1: NASDAQ:PRTA
Exchange/Ticker 2: N/A
Latest Market Cap: $653,459,776
BioCentury | Jan 18, 2025
Product Development
2025 catalysts: New modality showdowns
Genetic therapies compete in the same indications, as degraders come of age
BioCentury | Oct 1, 2024
Management Tracks
Prothena names Swanson CDO
Plus: Chris Williams at the helm of Culture, GentiBio scoops up former Structure CMO and updates on Burning Rock, National Resilience and Grünenthal
BioCentury | Jun 11, 2024
Product Development
What neuroscience biotechs need to consider when pitching VCs, pharmas
Investors and partners may have different priorities, but all want to see programs grounded in human data
BioCentury | Jun 4, 2024
Deals
Deals Report: Two pharmas license neuro assets, and M&A momentum continues
Plus: Galapagos-Adaptimmune enter TCR T cell deal, and digital therapeutics pioneer Akili opts for merger
BioCentury | May 10, 2024
Management Tracks
Nickerson to lead Therini as CEO
Plus: Alex Gorsky joins Iconiq Capital and updates from JPMorgan and Merakris
BioCentury | Mar 6, 2024
Management Tracks
EyePoint names Ribeiro CMO
Plus: Ford joins Prothena and updates from Atlas, Osmol and CytoVale
BioCentury | Feb 23, 2024
Management Tracks
New chair, management changes at Ocular
Plus: Jason Gammack named CEO of Ansa, and updates from LenioBio, Prothena and Ikena
BioCentury | Aug 31, 2023
Finance
Formulas for success from biotechs that leaped in value despite the downturn
Back to School 2023 identifies four themes among 17 companies that jumped a tier or increased their market cap over 200%
BioCentury | Jul 10, 2023
Deals
July 10 Quick Takes: Astellas licenses 4D’s AAV vector
Plus: J&J partners with Nanobiotix and updates from CMS, WuXi, BeiGene and more
BioCentury | May 17, 2023
Management Tracks
FDA veteran Dunn to join Prothena’s board
Plus: Lucera named CFO at Editas, and updates from Erasca, Sangamo, AlloVir and more
Items per page:
1 - 10 of 123